SMT C1100 For Duchenne Muscular Dystrophy Moves To Human Testing - MarketWatch: The Muscular Dystrophy Association announced today that SMT C1100, an experimental drug for Duchenne muscular dystrophy (DMD), has received approval from regulatory agencies in the United Kingdom to move from laboratory to human testing, starting with healthy human volunteers.
The drug is designed to increase production of a muscle protein utrophin that can potentially compensate for the one that's missing in DMD.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment